Condition: Myopia, Moderate · Myopic Astigmatism · Myopia, Degenerative · Sponsor: Biotech Healthcare Holding Gmbh
Primary Objective: To compare the efficacy and the residual refractive error of EYECRYLTM Phakic toric versus Visian® Toric ICL in moderate to high myopic patient with co-existing astigmatism. Secondary Objectives: To evaluate and compare the safety of EYECRYLTM Phakic toric versus Visian® Toric ICL in moderate to high myopic patients with co-existing astigmatism.
This description comes directly from the study's public registry record.
BHARGAV D JOSHI, M.Sc. · 917966823000 · bhargav.joshi@biotechhealthcare.com
Hatice B Deveci Summer, B.Sc · 0491739106424 · basak.deveci@biotechhealthcare.com
Always discuss trial participation with your own doctor first.
| Precise Vision Augentagesklinik Greven | Münster, North Rhine-Westphalia, Germany | Recruiting |
| Precise Vision Augentagesklinik Rheine | Rheine, North Rhine-Westphalia, Germany | Recruiting |
| Precise Vision Augentagesklinik Rheine | Steinfurt, North Rhine-Westphalia, Germany | Recruiting |
| Netradhama Superspeciality Eye Hospital | Bangalore, Karnataka, India | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06839898